The Nasal Covid-19 vaccine's clinical trial completed by Bharat Biotech.
The world's first nasal Covid-19 vaccine with clinical proof has successfully completed a clinical study, according to Dr. Krishna Ella, chairman and MD of Bharat Biotech. There is data analysis going on. The data will be provided to the regulating body. If all goes according to plan, we will be given the go-ahead to introduce the world's first nasal Covid-19 vaccination ANI cited Dr. Krishna Ella as saying. Bharat Biotech has received "in-principle" clearance from the Drugs Controller General of India (DCGI) Subject Expert Committee (SEC) for the "phase-III booster dosage trial" of its intranasal Covid vaccine, a first for India, and was asked to submit protocols for approval. According to the website of Bharat Biotech, an intranasal vaccination induces a broad immune response that neutralises IgG, mucosal IgA, and T cell responses as well as a local immune response (in the nasal mucosa) that is crucial for preventing Covid-19 infection and transmission. The second business to apply for the phase-III study of the third dosage in India is Bharat Biotech. According to reports, the intranasal vaccinations may be able to stop the spread of novel Covid-19 subtypes like Omicron.
Reference: - https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotechs-covid-19-nasal-vaccine-phase-iii-trials completed/articleshow/92311109.cms?from=mdr